Published in Circulation on February 28, 2012
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke (2014) 1.98
Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol (2013) 1.71
Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study. Stroke (2013) 1.47
High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J (2014) 1.41
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J (2016) 1.14
A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc (2013) 1.14
Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke (2013) 1.11
An update on the prognosis of patients with atrial fibrillation. Circulation (2012) 1.09
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. Am Heart J (2013) 0.88
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis (2017) 0.88
Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry. Clin Res Cardiol (2015) 0.86
Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management. Biomark Insights (2013) 0.85
Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord (2013) 0.82
Plasma B-type natriuretic peptide as a predictor of cardiovascular events in subjects with atrial fibrillation: a community-based study. PLoS One (2013) 0.82
Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One (2015) 0.81
Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection. Clin Res Cardiol (2013) 0.81
Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. J Saudi Heart Assoc (2014) 0.80
Almanac 2015: atrial fibrillation research in Heart. Heart (2016) 0.80
Prediction of atrial fibrillation development and progression: Current perspectives. World J Cardiol (2016) 0.80
Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability. Dis Markers (2015) 0.77
The association of CHA2DS2-VASc score and blood biomarkers with ischemic stroke outcomes: the Belgrade stroke study. PLoS One (2014) 0.77
Cardioembolic stroke diagnosis using blood biomarkers. Curr Cardiol Rev (2013) 0.77
Association between left atrial low-voltage area, serum apoptosis, and fibrosis biomarkers and incidence of silent cerebral events after catheter ablation of atrial fibrillation. J Interv Card Electrophysiol (2015) 0.77
Diagnosing Paroxysmal Atrial Fibrillation: Are Biomarkers the Solution to This Elusive Arrhythmia? Biomed Res Int (2015) 0.76
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. Scientifica (Cairo) (2014) 0.76
Risk stratification of patients with atrial fibrillation: Biomarkers and other future perspectives. World J Cardiol (2012) 0.75
Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification? J Atr Fibrillation (2013) 0.75
Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75
Determinants of Left Atrial Volume in Patients with Atrial Fibrillation. PLoS One (2016) 0.75
Atrial high-rate episodes and stroke prevention. Europace (2017) 0.75
Mean corpuscular volume and red cell distribution width as predictors of left atrial stasis in patients with non-valvular atrial fibrillation. Am J Cardiovasc Dis (2013) 0.75
Association of stroke risk biomarkers with stroke symptoms: the Reasons for Geographic and Racial Differences in Stroke cohort. J Thromb Haemost (2016) 0.75
Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy. J Interv Card Electrophysiol (2015) 0.75
Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing. BMC Cardiovasc Disord (2016) 0.75
Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nat Rev Cardiol (2016) 0.75
Stroke in Atrial Fibrillation - Long-term Follow-up of Cardiovascular Events. Arrhythm Electrophysiol Rev (2013) 0.75
Risk Stratification in Atrial Fibrillation Patients - A Review Focused on Mortality. Arrhythm Electrophysiol Rev (2012) 0.75
Impact of BNP level and peak VO2 on future heart failure events: comparison between sinus rhythm and atrial fibrillation. Heart Vessels (2016) 0.75
Patients with atrial fibrillation complicated by coronary artery disease. Is a single value of sensitive cardiac troponin I on admission enough? Herzschrittmacherther Elektrophysiol (2015) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet (2009) 7.62
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Amiodarone versus sotalol for atrial fibrillation. N Engl J Med (2005) 5.01
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50